Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q3 2018 (← Previous) (Next →)

Filing Date: Nov 14, 2018

Total Value ($000): $480,886 (100.0% shares, 0.0% debt)

Holdings (8)

— EYEPOINT 31.1%

Value ($000) $149,597 Shares 41,903,956 Est. Cost $2.49 Unrealized —

AXGN AXOGEN INC 28.4%

Value ($000) $136,754 Shares 3,711,111 Est. Cost $4.01 Unrealized +989.5%

— CORIUM 18.5%

Value ($000) $88,950 Shares 9,353,304 Est. Cost $7.77 Unrealized —

— REVANCE THERAPEUTICS INC 17.3%

Value ($000) $83,050 Shares 3,342,047 Est. Cost $31.50 Unrealized —

MNOV MEDICINOVA INC 3.0%

Value ($000) $14,618 Shares 1,170,370 Est. Cost $2.95 Unrealized +240.7%

— ENDOLOGIX INC 1.4%

Value ($000) $6,684 Shares 1,257,468 Est. Cost $18.00 Unrealized —

— CATALYST 0.2%

Value ($000) $861 Shares 78,622 Est. Cost $4.80 Unrealized —

ACUR ACURA PHARMACEUTICALS INC 0.1%

Value ($000) $372 Shares 1,956,397 Est. Cost $3.40 Unrealized -93.0%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	EYEPOINT	41,903,956	$149,597	31.1%	$2.49	—	COM	74440J101
AXGN	AXOGEN INC	3,711,111	$136,754	28.4%	$4.01	+989.5%	COM	05463X106
—	CORIUM	9,353,304	$88,950	18.5%	$7.77	—	COM	21887L107
—	REVANCE THERAPEUTICS INC	3,342,047	$83,050	17.3%	$31.50	—	COM	761330109
MNOV	MEDICINOVA INC	1,170,370	$14,618	3.0%	$2.95	+240.7%	COM	58468P206
—	ENDOLOGIX INC	1,257,468	$6,684	1.4%	$18.00	—	COM	29266S106
—	CATALYST	78,622	$861	0.2%	$4.80	—	COM	14888D109
ACUR	ACURA PHARMACEUTICALS INC	1,956,397	$372	0.1%	$3.40	-93.0%	COM	00509L802